US Edition
GeneCentric’s Funding Highlights Growing Investor Interest in RNA-Driven Diagnostics in Precision Oncology: GlobalData
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
GeneCentric’s funding highlights growing investor interest in RNA-driven diagnostics in precision oncology: GlobalData
GeneCentric Therapeutics has recently secured $8 million in new funding to advance its RNA-based liquid biopsy platform. The financing will support the development and commercialisation of GeneCentric’s platform, which enables non-invasive tumour profiling to guide treatment decisions and monitor disease progression. The funding reflects the growing investor enthusiasm for RNA-driven diagnostics in precision oncology, according to GlobalData. Ge…
GeneCentric’s funding highlights growing investor interest in RNA-driven diagnostics in precision oncology, says GlobalData
GeneCentric Therapeutics has recently secured $8 million in new funding to advance its RNA-based liquid biopsy platform. The financing will support the development and commercialization of GeneCentric’s platform, which enables non-invasive tumor profiling to guide treatment decisions and monitor disease progression. The funding reflects the growing investor enthusiasm for RNA-driven diagnostics in precision oncology, according to GlobalData, a l…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium